FARE Clinical Trial Finder

Simplify your search for a clinical trial and help researchers discover new therapies. The FARE Clinical Trial Finder links patients with food allergy and healthy, non-patient volunteers to actively recruiting food allergy studies.

Mite Asthma Pediatric Immunotherapy Trial

Study Purpose

The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma worsening.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 5 Years - 17 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Written informed consent - Male or female of any race/ethnicity aged 5-17 years - A female subject of childbearing potential must have a negative pregnancy test and be willing to practise appropriate contraceptive methods - A clinical history of HDM allergic asthma - Use of low daily dose of ICS plus LABA or medium/high daily dose of ICS with or without LABA for the control of asthma symptoms - A clinical history of asthma exacerbations in the past two years - One or more of the following within the past 4 weeks prior to randomisation: - Daytime asthma symptoms more than twice/week - Any nocturnal awakening due to asthma - SABA rescue medication needed for treatment of asthma symptoms - Any activity limitation due to asthma - Lung function measured by FEV1 ≥ 70% of predicted value or according to local requirements - Clinical history of HDM AR within the last year prior to randomisation - An average TCRS>0 during the baseline period - Positive specific IgE (defined as ≥class 2, ≥0.70 kU/l) against D.
pteronyssinus and/or D. farinae at screening
  • - Positive SPT to D.
pteronyssinus and/or D. farinae at screening
  • - Subject willing and able to comply with trial protocol

    Exclusion Criteria:

    - Is sensitised and regularly exposed to animal dander, molds, and/or cockroach or other perennial allergen - Has experienced a life-threatening asthma attack - Within the last month before the randomisation visit (visit 3), has had an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalisation, or treatment with systemic corticosteroids - Within the last 3 months before the randomisation visit (visit 3) while on high dose ICS treatment, has had an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalisation, or treatment with systemic corticosteroids - Any SLIT or SCIT treatment with D.
pteronyssinus or D. farinae within the previous 12 months
  • - Ongoing treatment with any allergy immunotherapy product - Any clinically relevant condition or chronic disease incl.
malignancy that in the opinion of the investigator would interfere with the trial evaluations or the safety of the subject
  • - Has a diagnosis of eosinophilic oesophagitis - A relevant history of systemic allergic reactions - Ongoing treatment with OCS - Treatment with restricted and prohibited concomitant medication - Treatment with an investigational drug within 30 days/5 half-lives of the drug (which ever longest) prior to screening - A history of allergy, hypersensitivity or intolerance to any of the excipients or active substance of the IMP (except D.
pteronyssinus and D. farinae) or to any excipient of the rescue medication provided in this trial - A business or personal relationship with trial staff or sponsor who is directly involved with the conduct of the trial - A history of alcohol or drug abuse - Has previously been randomised into this trial, is participating in this trial at another investigational site or is participating or planning to participate in any other clinical trial during the duration of this trial - Has a history or current evidence of any condition, treatment, laboratory values out of range or other circumstance that in the opinion of the investigator are clinically relevant and might expose the subject to risk by participating in the trial, confound the results of the trial, or interfere with the subject's participation for the full duration of the trial - Has a condition or treatment that increase the risk of the subject developing severe adverse reactions after adrenaline/epinephrine administration - Is unable to or will not comply with the use of adrenaline/epinephrine auto-injectors for countries where this is a regulatory requirement

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03654976
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

ALK-Abelló A/S
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Hungary, Poland, United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Additional Details

The trial aims to demonstrate efficacy of the HDM SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with HDM allergic asthma based on clinically relevant asthma exacerbations. Additionally, the trial will investigate if the treatment has an effect on asthma symptoms including nightly awakenings due to asthma, asthma medication use, asthma control, lung function, allergic rhinitis and allergic rhinoconjunctivitis. Finally, quality of life (QoL) for subjects and caregivers will be measured. The trial is a randomised, parallel-group, double-blind, placebo-controlled multi-national phase III trial conducted in Europe and North America. The treatment period will be approximately 2 years. Subjects will receive a written asthma action plan.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Southampton General Hospital, Southampton, United Kingdom

Status

Recruiting

Address

Southampton General Hospital

Southampton, ,

Site Contact

Roberts, MD

clinicaltrials@alk.net

+45 4574 7576

Ostrowieckie Centrum Medyczne S.C., Ostrowiec Świętokrzyski, Poland

Status

Recruiting

Address

Ostrowieckie Centrum Medyczne S.C.

Ostrowiec Świętokrzyski, ,

Site Contact

Olech-Cudzik, MD

clinicaltrials@alk.net

+45 4574 7576

Aranyklinika Kft, Szeged, Hungary

Status

Recruiting

Address

Aranyklinika Kft

Szeged, ,

Site Contact

Novak, MD

clinicaltrials@alk.net

+45 4574 7576

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.